SCHEMBL20135688

SCHEMBL20135688

CCOC(=O)c1ccc(C(C#N)(CC)C(=O)OC(C)(C)C)nc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.38
KMT2A Q03164 3/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
MEN1 O00255 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPK1 P28482 1/20 0.38
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA7 P43166 2/20 0.37
CA9 Q16790 2/20 0.37
CA14 Q9ULX7 2/20 0.37
ESR1 P03372 1/20 0.37
ESR2 Q92731 1/20 0.37
NPSR1 Q6W5P4 2/20 0.37
KDM4E B2RXH2 3/20 0.36
TSHR P16473 1/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135150 0.90 MAPT (0.36) MAPTKMT2ANPC1RAB9AMEN1
SCHEMBL20134843 0.83 MAPT (0.40) MAPTKMT2ANPC1RAB9AMEN1
SCHEMBL20135375 0.76 MAPT (0.41) MAPTKMT2ANPC1RAB9AMEN1
SCHEMBL12868073 0.76 KMT2A (0.54) MAPTKMT2ANPC1RAB9AMEN1
SCHEMBL20134842 0.72 SMN1; SMN2 (0.49) MAPTKMT2ANPC1RAB9AMEN1
SCHEMBL838555 0.72 CA12 (0.49) MAPTKMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL20135239 0.70 MAPT (0.39) MAPTKMT2ANPC1RAB9AMEN1
SCHEMBL20135236 0.70 MAPT (0.39) MAPTKMT2ANPC1RAB9AMEN1
SCHEMBL4778427 0.70 MAPK1 (0.51) MAPTKMT2ANPC1RAB9AMEN1
SCHEMBL20791725 0.70 CA12 (0.36) MAPTKMT2ANPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 MAPT 4505/4885KMT2A 2568/4885NPC1 4881/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 MAPT 4265/4885KMT2A 2539/4885NPC1 4882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.